In published studies, TRC102 was found to potentiate the antitumor effect of TMZ and carmustine in several murine xenograft models of colon cancer, regardless of cell line genetics, including the status of MGMT, MMR, or p53, potentially providing a route to MGMT status-independent TMZ activity [5]. The gene discussed is MGMT; the disease is malignant colon neoplasm.